



Yes, you can.®

**2011 Shareholder Meeting
May 19, 2011**



Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. Terms such as “will,” “should,” “could”, “plan,” “intend,” “expect,” “continue,” “forecast,” “believe,” “anticipate” and “seek,” as well as similar comments, are forward-looking in nature. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual results and events may differ significantly from those expressed or anticipated as a result of risks and uncertainties which include, but are not limited to, the following: adverse changes in government and other third-party payor reimbursement levels and practices (such as, for example, the Medicare bidding program covering nine metropolitan areas beginning in 2011 and an additional 91 metropolitan areas beginning in 2013), impacts of the U.S. health care reform legislation that was recently enacted (such as, for example, the excise tax beginning in 2013 on medical devices, together with further regulations to be promulgated by the U.S. Secretary of Treasury, if adopted); legal actions, regulatory proceedings or governmental investigations (including, for example, compliance costs or other adverse effects of enforcement actions which could arise from the Company’s current, ongoing FDA investigations); product liability claims; extensive government regulation of the Company’s products; failure to comply with regulatory requirements or receive regulatory clearance or approval for the Company’s products or operations in the United States or abroad; the uncertain impact on the Company’s providers, on the Company’s suppliers and on the demand for the Company’s products resulting from the current global economic conditions and general volatility in the credit and stock markets; loss of key health care providers; exchange rate and tax rate fluctuations; inability to design, manufacture, distribute and achieve market acceptance of new products with higher functionality and lower costs; consolidation of health care providers and the Company’s competitors; lower cost imports; uncollectible accounts receivable; difficulties in implementing/upgrading Enterprise Resource Planning systems; risks inherent in managing and operating businesses in many different foreign jurisdictions; ineffective cost reduction and restructuring efforts; potential product recalls; natural disasters that lead to supply chain disruptions beyond the Company’s control; possible adverse effects of being leveraged, which could impact the Company’s ability to raise capital, limit its ability to react to changes in the economy or the health care industry or expose the Company to interest rate or event of default risks; increased freight costs; inadequate patents or other intellectual property protection; incorrect assumptions concerning demographic trends that impact the market for the Company’s products; decreased availability or increased costs of materials which could increase the Company’s costs of producing or acquiring the Company’s products, including possible increases in commodity costs; the loss of the services of or inability to attract and maintain the Company’s key management and personnel; inability to acquire strategic acquisition candidates because of limited financing alternatives; increased security concerns and potential business interruption risks associated with political and/or social unrest in foreign countries where the Company’s facilities or assets are located; provisions of Ohio law or in the Company’s debt agreements, shareholder rights plan or charter documents that may prevent or delay a change in control, as well as the risks described from time to time in Invacare’s reports as filed with the Securities and Exchange Commission. Except to the extent required by law, we do not undertake and specifically decline any obligation to review or update any forward-looking statements or to publicly announce the results of any revisions to any of such statements to reflect future events or developments or otherwise.

World's Largest Manufacturer and Distributor of Home Medical Equipment



- \$1.7 billion company (NYSE: IVC) selling to over 25,000 home healthcare and medical equipment providers worldwide.
- Five primary product groups:
 - Rehab Products
 - Standard Products
 - Respiratory Products
 - Medical Supplies
 - Continuing Care / Other Products
- Equity market capitalization of approximately \$1.1 billion as of 4/29/11
- Enterprise value of approximately \$1.3 billion*



One-Stop Shopping

Sales by Product – (12/31/10)



Continuing Care / Other
9%



Standard
36%



Rehab
30%



Respiratory
8%



Medical Supplies
17%

Industry Leading Worldwide Market Positions


➤ We are the #1 player in most product lines

	Invacare	Sunrise*	DeVilbiss*	Pride*	Drive*	Medline*	Handi-care*	Permobil*	Res-pironics
Powered Mobility (excluding scooters)	#1	●		#2			●	●	
Manual Mobility (active)	#1	#2					●		
Manual Mobility (low-active)	#1	●			●	●	●		
Personal Care	#1				●	●	●		
Beds & Furnishings	#1	●			●	●			
Respiratory Therapy (excluding sleep)	#1		●						●
Patient Handling	●	●							
Medical Supplies	●					●			

* Private Company #1 Market Leader ● Second Tier ● Small Share

Geographically Diverse

Sales & Earnings Before Taxes by Geography - (12/31/10)



Based on 2010 segment data as reported in February 3, 2011 earnings release. EBT excludes unallocated corporate SG&A and intercompany profits.

Global Product Innovator



Yes, you can.®



Invacare® HomeFill® Oxygen System with Perfecto2® Oxygen Concentrator and M2 Cylinder



Invacare® XPO2™ Portable Concentrator



Invacare® Solo2® Transportable Oxygen Concentrator



Invacare® FDX® Power Wheelchair



Invacare® Action™ Manual Wheelchair
(Introducing this chair as the Invacare® Myon™ in U.S.)

Expanding Opportunities - Services

- Invacare Corporation now offers services to help U.S. home and long-term care providers respond to the challenges associated with accreditation, escalating operating costs and changes in Medicare reimbursement.



Nationwide network of technicians focused on repair of consumer power wheelchairs today (Roadrunner)



Wide range of replacement parts for most OEMs' equipment

Invacare Rentals

Short term renting of products such as support surfaces, beds, bariatric products, etc., to long-term care and skilled nursing providers



An integrated suite of online solutions that automate how homecare providers run and manage their business

Invacare Service & Parts

Replacement parts and after-market repair services for Invacare equipment



Patient management services for homecare providers including billing and collection support on the copay

Focus – Near Term Objectives

- Improve profitability and report adjusted EPS⁽²⁾ in 2011 of \$2.05 - \$2.15⁽¹⁾
- In 2011, approximately 3% - 4% organic net sales growth
- Reduce cost by continuing to rationalize product complexity in the supply chain

(1) All guidance constitutes forward-looking statements (see the risks described on page 2) and is given only as of the date of the last press release discussing quarterly earnings. We are not updating or reconfirming such guidance.

(2) Adjusted EPS is a non-GAAP financial measure as defined in the relevant year-end earnings release which can be found on www.invacare.com.



Historic Results & 2011 Financial Objectives

	<u>2008 Result</u>	<u>2009 Result</u>	<u>2010 Result</u>	<u>2011 Guidance⁽¹⁾</u>
Organic Growth	7%	-0.2%	1%	3% - 4%
Adjusted EPS ⁽²⁾ : Target / Actual	\$1.35 ⁽³⁾	\$1.58 ⁽³⁾	\$1.84 ⁽³⁾	\$2.05 - \$2.15
% Incr. vs Prior Year	21%	17%	16%	11% - 17%
Free Cash Flow ⁽²⁾	\$60 million	\$142 million	\$105 million	\$85 - \$95 million
Stock Price as of year end	\$15.52	\$24.94	\$30.16	

(1) All guidance constitutes forward-looking statements (see the risks described on page 2) and is given only as of the date of the last press release discussing quarterly earnings (4/28/11). We are not updating or reconfirming such guidance.

(2) Adjusted EPS and Free Cash Flow are non-GAAP financial measures as defined in the relevant year-end earnings release which can be found on www.invacare.com.

(3) GAAP EPS was \$1.09 in 2008; \$1.29 in 2009; and \$0.78 in 2010 (decrease 2010 versus 2009 related to fees from the Company's decision to extinguish higher interest rate debt)

Recent Refinancing Activity

- On October 28, 2010, Invacare announced the completion of a new Credit Agreement establishing a \$400 million senior secured revolving credit facility maturing in October 2015. The interest rate on borrowings is determined by adding a margin of 2.5% to both LIBOR and Base Rate Option loans.
- Upon establishing the new credit facility, Invacare announced a tender offer for its remaining \$146 million in outstanding principal amount of the Company's 9 ³/₄% senior notes due 2015. The Company redeemed 98% of the outstanding senior notes during the tender offer. The Company redeemed the remaining senior notes on December 31, 2010.
- On April 5, 2011, the Company entered into an amendment to its credit agreement that reduces the applicable interest rate related to both LIBOR and Base Rate Option borrowings by 75 basis points.
- Covenants within the new credit agreement allow the Company to resume its stock repurchase program.


Focus - Long Term Objectives

- Return to 4 – 5% Organic Net Sales Growth
 - Expand our core business – Maximize existing product categories within existing geographies. Increase spending in research and development through glocalization reinvestment.
 - Explore new business opportunities beyond our traditional product mix, such as clinical therapies that are moving and have moved into the home.
 - Move into new geographies like Latin America and China.

- Return to acquisitions

- Return to historical profitability
 - Organic net sales growth of 4 - 5% will allow the company to leverage its existing SG&A.
 - Globalization benefits expected to aggregate \$100 million over five years will drive gross margin expansion while allowing for increased R&D and offsetting pricing/reimbursement pressure over time. The company will target to double R&D spending over this time period.


Globalization - Timeline



Over the course of the five year program, where does the \$100 million benefit come from?

- Grow the Core
- Cost Out
- Operational & Lean
- SG&A

Globalization - Transformation Cycle



Investment Highlights

Invacare is a well positioned company ...

- Industry leading market positions
- Strong brand reputation with superior and innovative products
- Complete range of home healthcare products
- Strong sales and marketing coverage without major exposure to single customer
- Geographically diversified revenue base
- Experienced management team with significant ownership
- Flexible sourcing capability
- Named to the 2011 Fortune 1000
- 393rd largest manufacturer in the U.S. and the 39th largest in Ohio – Source: Industry Week

... in an industry with strong underlying fundamentals

- Positive demographic trends
- Compelling benefits of home care as opposed to institutional care